Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1069 - Safety profile and effectiveness of alectinib in the real world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Targeted Therapy

Tumour Site


Yuichiro Ohe


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


Y. Ohe1, N. Yamamoto2, A. Gemma3, M. Kusumoto4, I. Yamada5, T. Ishii6, N. Masuda7

Author affiliations

  • 1 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Third Department Of Internal Medicine, Wakayama Medical University, 6418509 - Wakayama/JP
  • 3 Division Of Pulmonary Medicine And Oncology, Nippon Medical School, 113-8603 - Tokyo/JP
  • 4 Department Of Diagnostic Radiology, National Cancer Center Hospital East, 2778577 - Kashiwa/JP
  • 5 Department Of Pharmacovigilance, Chugai Pharmaceutical Co.,Ltd., 103-8324 - Chuo-ku, Tokyo/JP
  • 6 Department Of Real World Data Science, Chugai Pharmaceutical Co., Ltd., 103-8324 - Tokyo/JP
  • 7 Division Of Clinical research Center, Izumi City General Hospital, 594-0071 - Osaka/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1069


Alectinib is a CNS penetrant and highly selective ALK inhibitor. The Japanese Risk Management Plan based on the phase I/II studies highlighted interstitial lung disease (ILD), liver function disorder, decreased neutrophil cell and white blood cell counts as identified risk in Japanese patients (pts). To investigate the safety and effectiveness of alectinib, including adverse drug reactions (ADR) of particular concern in the real world setting, a large scale surveillance funded by Chugai Pharmaceuticals has been implemented. This study is registered with the UMIN, number UMIN000014989.


From Sep 2014 to June 2015 all pts with ALK-positive recurrent/advanced NSCLC treated with alectinib, were enrolled in the study. The observation period was 18 months, ADR were collected. Overall survival (OS) was also assessed.


By Jun 2015, a total of 1251 pts were registered. We analysed 1221 pts as the safety population. Baseline characteristics included: female (54% of population), median age (62 years), ECOG PS 3-4 (n = 89) (7%), pts who received first line (18%), second line (32%) or third line or more (50%) treatments, pts who received crizotinib (63%), brain metastases (41%). The overall incidence of ADRs was 53.6% (mostly grade 1/2), the most common were laboratory tests abnormality (27.7%). ILD events were reported in 47 pts (3.8% of population), including grade 3 events in 8 pts and grade 4 events in 1 pt, in which the rate of recovery or improvement was 92%. Events of liver function disorder were reported in 242 pts (19.8%), including grade 3 events in 24 pts, and events of neutrophil cell and white blood cell decrease were reported in 93 pts (7.6%), including grade 3 events in 12 pts and grade 4 events in 2 pts, in which the rates of recovery or improvement were 83% and 93%, respectively. Median OS was not reached. Overall survival rate at 12 months and 18 months were 82.4% and 76.2%, respectively.


These final data from this study in Japanese ALK-positive NSCLC pts provide an acceptable safety and effectiveness profile in the real-world setting. Alectinib was primarily one of the effective therapies for the treatment of ALK-positive NSCLC.

Clinical trial identification

Legal entity responsible for the study

Chugai Pharmaceutical CO., LTD.


Chugai Pharmaceutical CO., LTD.

Editorial Acknowledgement


Y. Ohe: Consuting or advisory role, honoraria: Chugai Pharm Co., Ltd.; Research funding to institution: Chugai Pharm Co., Ltd. N. Yamamoto: Consuting or advisory role, speakers' bureau, honoraria: Chugai Pharm Co., Ltd. Research funding to instution: Chugai Pharm Co., Ltd. A. Gemma, M. Kusumoto, N. Masuda: Consuting or advisory role: Chugai Pharm CO., LTD. I. Yamada, T. Ishii: Employment: Chugai Pharm Co., Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.